Clinical Research Directory
Browse clinical research sites, groups, and studies.
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Sponsor: Caribou Biosciences, Inc.
Summary
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Official title: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2021-05-26
Completion Date
2026-12-31
Last Updated
2026-10-19
Healthy Volunteers
No
Conditions
Interventions
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.
Cyclophosphamide
Chemotherapy for lymphodepletion
Fludarabine
Chemotherapy for lymphodepletion
Locations (38)
University of Alabama at Birmingham
Birmingham, Alabama, United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
HonorHealth
Scottsdale, Arizona, United States
University of Arizona Cancer Center
Tucson, Arizona, United States
University of Arkansas
Little Rock, Arkansas, United States
University of California San Diego Moores Cancer Center
La Jolla, California, United States
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California, United States
Chao Family Comprehensive Cancer Center/University of California Irvine
Orange, California, United States
Advent Health
Orlando, Florida, United States
Bone and Marrow Transplant Group of Georgia
Atlanta, Georgia, United States
Augusta University/Georgia Cancer Center
Augusta, Georgia, United States
University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States
University of Kentucky
Lexington, Kentucky, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Tufts Medical Center
Boston, Massachusetts, United States
Regional Cancer Care Associates LLC - Hackensack
Hackensack, New Jersey, United States
Atlantic Health System
Morristown, New Jersey, United States
NYU Langone Health
New York, New York, United States
Montefiore Medical Center
New York, New York, United States
Oncology Hematology Care
Cincinnati, Ohio, United States
Ohio State University Medical Group
Columbus, Ohio, United States
Oregon Health & Science University (OHSU)
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Virginia Commonwealth University (VCU)
Richmond, Virginia, United States
Swedish Cancer Institute
Seattle, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Westmead Hospital
Westmead, New South Wales, Australia
Epworth Healthcare
Richmond, Victoria, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
The Tel Aviv Sourasky Medical Center
Tel Aviv, Tel Aviv-Yafo, Israel
Hadassah Medical Center
Jerusalem, Israel
Rabin Medical Center - Beilinson Hospital
Petah Tikva, Israel
The Sheba Fund for Health Services and Research (R.A.)
Tel Litwinsky, Israel